medigraphic.com
ISSN 1727-897X (Electronic)

2021, Number 1

<< Back Next >>

Medisur 2021; 19 (1)

Effectiveness of Cucurbita pepo in the prostatic hyperplasia treatment. Systematic review and meta-analysis

Ávila CJA, García MFM, Rodríguez VEC, Peña VA

Language: Spanish
References: 17
Page: 157-165
PDF size: 339.76 Kb.


ABSTRACT

Background: Benign prostatic hyperplasia is the most common benign tumor in men. The oil extracted from the pumpkin seed (Curcubita pepo) is used to treat the symptoms associated with this disease. However, human studies are few, and insufficient available evidence.
Objectives: to determine the effectiveness of pumpkin seed in the treatment of benign prostatic hyperplasia. To carry out a systematic review and meta-analysis on it.
Methods: a systematic review and meta-analysis of the existing literature in the Pubmed / Medline, Ebsco, Scopus and Scielo databases were carried out. Randomized clinical trials were selected, in any language that evaluated the effectiveness of phytomedicines composed of Cucurbita pepo, comparing it with a placebo; in patients with a proven diagnosis of prostatic hyperplasia; and with an evaluation time greater than six months.
Results: the total population in the selected studies was 1403 men, all over 50 years of age. All studies evaluated the effectiveness of pumpkin seed oil. The global mean difference was significant (MD: -0.76 95% CI: -1.40, -0.13, I2 = 26.75%). No significant improvement was found in terms of quality of life, uroflowmetric parameters, residual volume, prostate surface antigen values, and prostate size.
Conclusion: The results showed, with a moderate level of evidence, that phytomedicines based on pumpkin seed or its extract were not associated with a clinical or functional improvement of benign prostatic hyperplasia.


REFERENCES

  1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96

  2. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016;43(3):289-97

  3. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario Estadístico de Salud 2019. La Habana: MINSAP; 2020

  4. Nickel JK, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC. Canadian urological association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J. 2018;12(10):303-12

  5. Linares A. Hiperplasia prostática benigna. En: Morón F. Farmacología Clínica. Vol 2. La Habana: Editorial Ciencias Médicas; 2009. p. 559-68

  6. Zhang W, Ma L, Bauer BA, Liu Z, Lu Y. Acupuncture for benign prostatic hyperplasia: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0174586

  7. Bae GE, Lee SH, Hong JW, Lee I, Kim S, Choi J, et al. Moxibustion for benign prostatic hyperplasia: a systematic review and meta-analysis. J Int Korean J Med. 2018;39(3):372-88

  8. Carbin EB, Larsson B, Lindahl O. Treatment of benign prostatic hiperplasia with phytosterols. Br J Urol. 1990;66(6):639-41

  9. Damiano R, Cai T, Fornara P, Franzese CA, Leonardi R, Mirone V. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: A narrative review. Arch Ital Urol Androl. 2016;88(2):136-43

  10. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. En: Higgins JPT, Green S, editores. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Internet]. London, UK: The Cochrane Collaboration; 2011 [citado 18/03/2020]. Disponible en: Disponible en: https://handbook-5-1.cochrane.org/

  11. Hamvas A, Corradi Gy, Hegedüs M, Frang D. Experience with the Peponen(r) capsule in the management of benign prostatic hyperplasia. Int Urol Nephrol. 1991;23(1):51-5

  12. Frederich M, Theurer C, Schiebel-Scholser G. Prosta Fink Forte(r)-Kaplsen in der Behandlung der benignen prostatahyperplasie. Forsch Komplementärmed Klass Naturheilkd. 2000;7(4):200-4

  13. Leibbrand M, Siefer S, Sch?n C, Perrinjaquet T, Kompek A, Csernich A, et al. Effects of an oil-free hydroethanolic pumpkin seed extract on symptom frecuency and severity in men with benign prostatic hyperplasia: a pilot study in humans. J Med Food. 2019;22(6):551-9

  14. Habib FK, Wyllie MG. Not all brands are created equal: A comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis . 2004;7(3):195-200

  15. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel C, et al. Effect of increasing doses of saw palmetto on lower urinary tract symptoms: A randomized trial. JAMA. 2011;306(12):1344-51

  16. Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;12(12):CD001423

  17. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;1998(1):CD001044




2020     |     www.medigraphic.com